Authors : Disha Bipinbhai Patel, Shilpa H Gandhi , Gauravi H Dhruva
Volume : 11
Issue : 2
Year : 2024
Page No : 1-7
Aims and Objectives: Classification of salivary gland lesions into 6 diagnostic categories by using Milan Reporting System. Calculate risk of malignancy (ROM) of each category in present study and compare with other similar study. Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) developed in 2015, aims of MSRSGC to standardize the reporting of salivary gland cytology. It provides a uniform diagnostic terminology that enhances communication between pathologists and clinicians. Moreover, it facilitates the evaluation of data and ensures a precise cytologic and histologic correlation of cases. Ultimately, this system is designed to improve patient care by streamlining the diagnosis process and enabling more accurate treatment decisions. Materials and Methods: Clinical history and cytology smears of salivary gland lesions, which were diagnosed from October 2022 to September 2023, were retrieved in a P.D.U. medical hospital in Rajkot, Gujarat. The cytology smears were all meticulously reviewed and subsequently classified into one of the six categories as prescribed by MSRSGC. With HPE considered the gold standard, the sensitivity, specificity, positive predictive value, and negative predictive value of FNAC for detecting malignant lesions were meticulously calculated. Results: A total of 59 salivary gland lesions underwent examination, of which 38 (64.4%) were found in males, and 21 (35.6%) were identified in females. The patients had a median age of 45 years, with ages ranging from 10 to 80 years. It was revealed through statistical analysis that the sensitivity, specificity, positive predictive value, and negative predictive value were determined to be 80%, 100%, 100%, and 88%, respectively. Conclusion: MSRSGC serves as an effective framework for the categorization of salivary gland tumors, be they benign or malignant. Our findings reflect the positive contribution of the MSRSGC towards accurately identifying the malignant lesions and thus further helping the clinicians regarding the specific management decisions.